New York State Psychiatric Institute

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, New York State Psychiatric Institute sits in the top decile of US sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count).

364 total trials 12 currently recruiting 296 completed early-phase tilt top decile by trial count

New York State Psychiatric Institute: 364 sponsored US clinical trials, 12 recruiting.

New York State Psychiatric Institute sponsors 364 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 296 completed. 80 of these trials are in Phase 3-4 (later-stage) and 152 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 10 trials.

Top-decile sponsor footprint

New York State Psychiatric Institute ranks in the top decile of sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

296 of 342 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

364 total, page 7 of 8

COMPLETED Phase 2

Dronabinol Treatment for Marijuana Addiction

NCT00217971

COMPLETED Phase 4

A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression

NCT00296699

COMPLETED Phase 4

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725

COMPLETED Phase 4

Are Two Antidepressants a Good Initial Treatment for Depression?

NCT00296712

COMPLETED NA

Effectiveness of Group Interpersonal Psychotherapy in Treating Women With Prenatal Depression

NCT00633178

COMPLETED Phase 4

Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)

NCT00219349

COMPLETED Phase 2

Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper

NCT00374127

COMPLETED Phase 4

Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS

NCT00118378

COMPLETED Phase 4

Treatment of Depression Following Multiple Brain Tests

NCT00296777

COMPLETED Phase 2

Transcranial Magnetic Stimulation (TMS) and Obsessive Compulsive Disorder (OCD)

NCT00106249

COMPLETED

Appetite-Related Brain Activity in Women With Anorexia Nervosa

NCT00344656

COMPLETED

Hormone Release and Stomach Disturbances in People With Binge Eating Disorder

NCT00307190

COMPLETED

An fMRI Study of Self-regulation in Adolescents With Bulimia Nervosa

NCT00345943

COMPLETED Phase 2

Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa

NCT00304187

TERMINATED Phase 2

Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)

NCT00517075

COMPLETED Phase 4

Antipsychotic Discontinuation in Alzheimer's Disease

NCT00417482

COMPLETED Phase 2

Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00218543

COMPLETED Phase 2

Prescription Opioid Effects in Abusers Versus Non-Abusers

NCT00158184

TERMINATED Phase 4

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

NCT00429169

COMPLETED Phase 3

HIV/STD Safer Sex Skills Groups for Women in Drug Treatment Programs - 1

NCT00084188

COMPLETED Phase 2

Treatment of Adolescent Suicide Attempters (TASA)

NCT00080158

COMPLETED Phase 2

Levetiracetam for the Treatment of Alcohol Dependence and Anxiety

NCT00141115

COMPLETED Phase 2

Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1

NCT00131456

COMPLETED NA

Effectiveness of High Intensity Inpatient Versus Stepped Intensity Treatment for Anorexia Nervosa

NCT00815815

COMPLETED Phase 3

Women's Treatment for Trauma and Substance Use Disorders - 1

NCT00078156

COMPLETED Phase 1

The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1

NCT00136747

COMPLETED Phase 4

Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa

NCT00685334

TERMINATED NA

Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa

NCT00308776

COMPLETED

Serotonin Transporter Concentrations in Women With a History of Anorexia Nervosa

NCT00320684

COMPLETED Phase 2

Therapeutic Cocaine Vaccine: Human Laboratory Study

NCT00965263

COMPLETED Phase 2

Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2

NCT00134901

COMPLETED NA

Improving Retention of Hispanics Receiving Antidepressant Therapy

NCT00057642

COMPLETED Phase 2

Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence

NCT00332228

COMPLETED NA

Critical Time Intervention in the Transition From Hospital to Community in People With Severe Mental Illness

NCT00621465

COMPLETED NA

Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2

NCT00136838

TERMINATED Phase 4

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

NCT00296686

COMPLETED Phase 3

Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

NCT00018863

COMPLETED NA

Enhancing the Outcome of Skills Training for People With Schizophrenia

NCT00069433

COMPLETED Phase 4

Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

NCT00533117

COMPLETED Phase 4

Optimizing Electroconvulsive Therapy for Depression

NCT00045916

COMPLETED Phase 1

Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

NCT00563992

COMPLETED NA

Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder

NCT00045903

COMPLETED NA

Clinical Trials of Two Non-drug Treatments for Chronic Depression

NCT00006172

COMPLETED Phase 3

Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults

NCT00218114

COMPLETED Phase 4

Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa

NCT00288574

COMPLETED Phase 2

Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals

NCT00249483

COMPLETED Phase 1

HIV Counseling Intervention for Methadone-Maintained Patients - 2

NCT00061100

COMPLETED Phase 2

Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1

NCT00238914

COMPLETED Phase 3

Treatment of Panic Disorder: Long Term Strategies

NCT00000368

COMPLETED Phase 4

Treatment of Behavioral Symptoms in Alzheimer's Disease

NCT00009217

← Previous Page 7 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 51
Phase 2 101
Phase 3 14
Phase 4 66

What is open in the New York State Psychiatric Institute pipeline

12 recruiting of 364 indexed (3% open); 296 completed (81%).

Phase mix: 80 late (III/IV) vs 152 early (I/II) (early-phase heavy).

Top condition: Depression (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

New York State Psychiatric Institute: open-pipeline peers nationwide

Peers matched on 364 registered trials and 3% open enrollment, not the therapeutic-area sidebar.

New York State Psychiatric Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%5%10%15%20%25% Total trials Recruiting share New York State Psychiatric InstituteRoswell Park Cancer InstituteUNC Lineberger Comprehensive Cancer CenterUniversity of California, IrvineNorthwell HealthBiotronikCharles Drew University of Medicine and ScienceKyntra BioHalozyme Therapeutics
New York State Psychiatric Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

New York State Psychiatric Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 364 trials (± recruiting share)

Sponsors near 3% open enrollment (± trial volume)

What to do with this New York State Psychiatric Institute page

364 registered trials is a research-attention snapshot, not an endorsement of New York State Psychiatric Institute or any single study.

  • 12 of New York State Psychiatric Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition New York State Psychiatric Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. New York State Psychiatric Institute pipeline card: 364 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.